Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01784133 · ClinicalTrials.gov registry record · Phase 2
A Twelve Week Safety and Efficacy Study in Rosacea
A Phase 2 study of Papulopustular Rosacea, sponsored by Maruho Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 17
- Study locations
NCT01784133: Completed Phase 2 study of Papulopustular Rosacea, sponsored by Maruho Co..
NCT01784133 is a Phase 2 study of Papulopustular Rosacea that has completed, run by Maruho Co.. The registered enrollment target is 240 participants, roughly in line with the 258-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target. The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01784133, a Phase 2 study of Papulopustular Rosacea, has completed, sponsored by Maruho Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to evaluate th safety and efficacy of one-daily topical application of CLS001 low, mid and high dose compared to vehicle gel in subjects with papulopustular rosacea.
Conditions Studied
Interventions
- DRUG placebo
- DRUG omiganan
Study Locations (17)
Florida
- Skin Care Research, Inc - Boca Raton
- Dunedin Research Specialists - Dunedin
- North Florida Dermatology Associates - Jacksonville
New York
- Rochester General Medical Group Center for Dermatology at Linden Oaks - Rochester
- Derm Research Center of NY Inc. - Stoney Brook
Tennessee
- TriCities Skin and Cancer - Johnson City
- Tennessee Clinical Research Center - Nashville
Alabama
- Radiant Research Inc. - Birmingham
California
- ATS Clinical Research - Santa Monica
Connecticut
- The Savin Center, PC - New Haven
Indiana
- Dawes Fretzin Clinical Research Group - Indianapolis
Michigan
- Grekin Skin Institute - Warren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2013-03 |
| Phase | Phase 2 |
What the finished NCT01784133 record still lists
NCT01784133 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 258-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target.
The record links to 1 condition, with Papulopustular Rosacea appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01784133 lists 17 locations in 13 states (Florida, New York, Tennessee).
Frequently Asked Questions
What is clinical trial NCT01784133 about?
NCT01784133 is a clinical study titled "A Twelve Week Safety and Efficacy Study in Rosacea". The purpose of this study is to evaluate th safety and efficacy of one-daily topical application of CLS001 low, mid and high dose compared to vehicle gel in subjects with papulopustular rosacea.
What is the current status of trial NCT01784133?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2013-03.
What conditions does trial NCT01784133 study?
This clinical trial studies the following conditions: Papulopustular Rosacea.
What interventions are being tested in trial NCT01784133?
The interventions under investigation include: placebo (DRUG), omiganan (DRUG).
Who is sponsoring clinical trial NCT01784133?
This trial is sponsored by Maruho Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01784133 being conducted?
This trial has 17 study locations across Alabama, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01784133's enrollment target sits among peer trials
240 5th of 11 higher than 7 of 11 other Papulopustular Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Papulopustular Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
COMPLETED · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
-
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia